Here are four notes:
1. The company’s underlying revenue increased by 3.8 percent year-to-year, led by strong performance in the U.S. and the emerging markets
2. It also reported an underlying core earnings increase of 1.5 percent year-to-year.
3. Underlying revenue from the gastroenterology market was up by 24.7 percent year-to-year.
4. Based on performance through three quarters, Takeda raised the full-year reported forecast for operating profit to 120 billion yen.
More articles on GI/endoscopy:
DuPage Medical Group acquires Midwest Digestive Disease Specialists: 3 things to know
8 must-reads on colonoscopy
5 things to know about office visit costs prior to screening colonoscopy
